Shield Therapeutics - Shelf-life for Accrufer® extended to 48 months

RNS Number : 2379E Shield Therapeutics PLC 27 October 2022   Shield Therapeutics plc ("Shield" or the "Company" or the "Group")   Shelf-life for Accrufer® extended to 48 months in the US   London, UK, 27 October 2022:  Shield Therapeutics plc (LSE: STX),  a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), announces that US Food and Drug Administration ('FDA') has approved the extension of the expiration for Accrufer® (ferric maltol) from 36 months to 48 months.   Greg Madison, CEO of Shield Therapeutics, stated: "Over the past year, we have doubled the shelf-life or time to expiry for Accrufer® from 24 to 48 months.  Not only does this confirm the stable and robust nature of the capsule formulation of Accrufer®, but also provides additional supply chain flexibility and simplifies global logistics as we continue to support our growing US business and our license partners across the globe."     For further information please contact:   Shield Therapeutics plc www.shieldtherapeutics.com Greg Madison, CEO +44 (0) 191 511 8500 Hans-Peter Rudolf, CFO     Nominated Adviser and Joint Broker   Peel Hunt LLP   James Steel/Christopher Golden +44 (0)20 7418 8900   Joint Broker finnCap Ltd      Geoff Nash/ George Dollemore/Alice Lane/Nigel Birks                                                   +44 (0)20 7220 0500     Financial PR & IR Advisor   Walbrook PR   Lianne Applegarth/Alice Woodings +44 (0)20 7933 8780 or [email protected]   Investor Contact (US Advisor) LifeSci Advisors, LLC John Mullaly     +1 617 429 3548 or [email protected]   About Accrufer®/Feraccru® Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of action compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com   About Shield Therapeutics plc Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada. Accrufer®/Feraccru® has patent coverage until the mid-2030s Accrufer®/Feraccru® are registered trademarks of the Shield Group This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.   END     MSCBUBDGUSDDGDL

The release as fetched from its publisher. shieldtherapeutics.com ↗